MCM
FATE icon

MAI Capital Management’s Fate Therapeutics FATE Stock Holding History

MAI Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88K Buy
+1,567
New +$1.91K ﹤0.01% 3950

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAI Capital Management's FATE Position: Q1 2026 in Review

MAI Capital Management opened a new position in Fate Therapeutics (FATE) in Q1 2026: 1,567 shares worth $1.88K. The stake represents ﹤0.01% of the portfolio and ranks #3950 among its holdings.

157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • MAI Capital Management held 1,567 shares of Fate Therapeutics worth $1.88K as of Q1 2026.
  • Fate Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3950 holding.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.